Patents by Inventor Arthur Pichler
Arthur Pichler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11192860Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).Type: GrantFiled: July 11, 2018Date of Patent: December 7, 2021Inventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
-
Patent number: 10842782Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.Type: GrantFiled: March 22, 2017Date of Patent: November 24, 2020Assignee: Sandoz AGInventors: Franz Xaver Schwarz, Arthur Pichler
-
Publication number: 20200262792Abstract: The present invention relates to a co-crystal of roxadustat with L-proline and to a process for its preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said roxadustat L-proline co-crystal, at least one pharmaceutically acceptable excipient and optionally at least one photostabilizing agent. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prevention of anemia in patients with end-stage renal disease (ESRD) and/or chronic kidney disease (CKD).Type: ApplicationFiled: July 11, 2018Publication date: August 20, 2020Applicant: Sandoz AGInventors: Hannes Lengauer, Arthur Pichler, Renate Margreiter, Thomas Gelbrich
-
Publication number: 20190008838Abstract: The present invention relates to a pharmaceutical composition containing a stable polymorph of rifaximin and a wicking agent as well as a method of preparing the same.Type: ApplicationFiled: March 22, 2017Publication date: January 10, 2019Applicant: Sandoz AGInventors: Franz Xaver Schwarz, Arthur Pichler
-
Patent number: 9732053Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.Type: GrantFiled: June 30, 2014Date of Patent: August 15, 2017Assignee: LEK PHARMACEUTICALS D.D.Inventors: Andreas Hotter, Robert Ziegert-Knepper, Verena Adamer, Arthur Pichler
-
Patent number: 9534004Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.Type: GrantFiled: December 19, 2013Date of Patent: January 3, 2017Assignee: SANDOZ AGInventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
-
Publication number: 20160289202Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.Type: ApplicationFiled: June 30, 2014Publication date: October 6, 2016Applicant: LEK PHARMACEUTICALS D.D.Inventors: Andreas HOTTER, Robert ZIEGERT, Verena ADAMER, Arthur PICHLER
-
Publication number: 20160200750Abstract: The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and ?-lactamase inhibitors.Type: ApplicationFiled: December 19, 2013Publication date: July 14, 2016Inventors: Josef Wieser, Hubert Sturm, Arthur Pichler, Andreas Hotter, Nolwenn Martin, Christoph Langes, Ulrich Griesser
-
Patent number: 9266868Abstract: Provided are a crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions containing the crystalline dihydrate and processes for preparing and storing the pharmaceutical compositions. Also provided are a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and the use of the Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.Type: GrantFiled: July 5, 2011Date of Patent: February 23, 2016Assignee: SANDOZ AGInventors: Johannes Ludescher, Hubert Sturm, Ulrich Griesser, Robert E. Ziegert-Knepper, Arthur Pichler, Mairi Haddow
-
Patent number: 9260389Abstract: The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.Type: GrantFiled: October 2, 2013Date of Patent: February 16, 2016Assignee: SANDOZ AGInventors: Arthur Pichler, Josef Wieser, Christoph Langes, Milica Vukicevic
-
Patent number: 9062031Abstract: The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition.Type: GrantFiled: December 21, 2011Date of Patent: June 23, 2015Assignee: SANDOZ AGInventors: Arthur Pichler, Andreas Hotter, Christoph Langes
-
Publication number: 20140294962Abstract: The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition.Type: ApplicationFiled: December 21, 2011Publication date: October 2, 2014Applicant: SANDOZ AGInventors: Arthur Pichler, Andreas Hotter, Christoph Langes
-
Patent number: 8785455Abstract: The present invention relates to a novel polymorph of Linagliptin benzoate and to methods for its preparation. Furthermore the present invention relates to the use of the novel polymorph for the preparation of a medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel polymorph of Linagliptin benzoate.Type: GrantFiled: May 9, 2012Date of Patent: July 22, 2014Assignee: Sandoz AGInventors: Andreas Hotter, Arthur Pichler
-
Publication number: 20140200252Abstract: The present invention relates to novel polymorphic forms of Saxagliptin Hydrochloride. The present invention also relates to methods of making polymorphic forms of Saxagliptin Hydrochloride.Type: ApplicationFiled: October 2, 2013Publication date: July 17, 2014Applicant: SANDOZ AGInventors: Arthur Pichler, Josef Wieser, Christoph Langes, Milica Vukicevic
-
Publication number: 20140121225Abstract: The present invention relates to a novel polymorph of Linagliptin benzoate and to methods for its preparation. Furthermore the present invention relates to the use of the novel polymorph for the preparation of a medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel polymorph of Linagliptin benzoate.Type: ApplicationFiled: May 9, 2012Publication date: May 1, 2014Applicant: SANDOZ AGInventors: Andreas Hotter, Arthur Pichler
-
Patent number: 8563555Abstract: The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.Type: GrantFiled: May 28, 2009Date of Patent: October 22, 2013Assignee: Sandoz AGInventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes, Christian Laschober
-
Publication number: 20130245017Abstract: The present invention relates to a novel crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline dehydrate and to processes for preparing and storing said pharmaceutical compositions. The invention also relates to a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and to the use of said Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.Type: ApplicationFiled: July 5, 2011Publication date: September 19, 2013Applicant: SANDOZ AGInventors: Johannes Ludescher, Hubert Sturm, Ulrich Griesser, Robert E. Ziegert-Knepper, Arthur Pichler, Mairl Haddow
-
Patent number: 8513224Abstract: The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament.Type: GrantFiled: December 18, 2009Date of Patent: August 20, 2013Assignee: Sandoz AGInventors: Andreas Hotter, Josef Wieser, Arthur Pichler, Martin Decristoforo
-
Patent number: 8435998Abstract: The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.Type: GrantFiled: June 25, 2009Date of Patent: May 7, 2013Assignee: Sandoz AGInventors: Josef Wieser, Arthur Pichler, Andreas Hotter, Ulrich Griesser, Christoph Langes
-
Publication number: 20130012481Abstract: The present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount and to the use of crystalline form A of Tigecycline hydrochloride as anti-infective medicament.Type: ApplicationFiled: July 17, 2012Publication date: January 10, 2013Applicant: SANDOZ AGInventors: Josef Wieser, Andreas Hotter, Arthur Pichler